Hongchao Liu

Mr. Hongchao Liu


Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 November 2014 in Biomedical Reports
Verified
Journal Article
Closed access
PDF file
LMLimin Ma
Limin Ma
HLHongchao Liu
Hongchao Liu
LRLinhai Ruan
Linhai Ruan
XYXuewen Yang
Xuewen Yang
HYHaiping Yang
Haiping Yang
YFYanming Feng
Yanming Feng
Several studies have investigated the association between multidrug resistance gene (MDR1) C1236T polymorphism and leukemia risk, however, these published studies have yielded conflicting results. Thus, the present study carried out a meta‑analysis to provide a more precise estimate of the effect of this polymorphism on the susceptibility to leukemia. The published case‑control studies regarding the association between MDR1 C1236T polymorphism and leukemia risk were included following a computerized search of PubMed, Elsevier, The Cochrane Library, China National Knowledge Infrastructure and Wanfang Database. Either fixed‑ or random‑effects models were applied to calculate the combined odds ratios (ORs) and 95% confidence intervals (CIs) by RevMan 5.2 software. Seven studies, including 846 cases and 1,523 controls, were included in the present meta‑analysis. The results indicated that there was no significant association between the MDR1 C1236T polymorphism and leukemia risk in overall comparisons in all four genetic models (CT vs. CC: OR, 1.31, 95% CI, 0.89‑1.91, P=0.17; TT vs. CC: OR, 2.16, 95% CI, 0.99‑4.70, P=0.05; TT vs. CC+CT: OR, 1.72, 95% CI, 0.91‑3.25, P=0.09; and CT+TT vs. CC: OR, 1.57, 95% CI, 0.96‑2.56, P=0.07). In the subgroup analysis according to specific ethnicity, age and the type of leukemia, a significant association was found in adult leukemia (CT+TT vs. CC: OR, 2.77, 95% CI, 1.05‑7.31, P=0.04) and chronic myeloid leukemia (CT vs. CC: OR, 1.71, 95% CI, 1.05‑2.80, P=0.03). No significant publication bias was detected by funnel plot. Therefore, the meta‑analysis indicated that the MDR1 C1236T polymorphism may contribute to the susceptibility to adult leukemia and chronic myeloid leukemia. Furthe well-designed studies based on larger sample sizes are required to validate these findings.

1 April 2014 in Asian Pacific Journal of Cancer Prevention
Verified
Journal Article
Open access
PDF file
SHShu Hu
Shu Hu
HLHongchao Liu
Hongchao Liu
SXShou-Ming Xi
Shou-Ming Xi
Several studies have investigated the association between methionine synthase reductase (MTRR) A66G polymorphism and breast cancer risk, but controversial results were yielded. Therefore, we performed a meta-analysis to provide a more robust estimate of the effect of this polymorphism on susceptibility to breast cancer.

1 January 2019 in Critical Reviews™ in Eukaryotic Gene Expression
Verified
Journal Article
Closed access
PDF file
HLHongchao Liu
Hongchao Liu
ZWZhihao Wei
Zhihao Wei
KSKangke Shi
Kangke Shi
YZYu Zhang
Yu Zhang
Several studies have investigated the relationship between ABCB1 G2677T/A polymorphism and breast cancer susceptibility, however, the published results remain controversial. Thus, a meta-analysis was conducted to synthetically evaluate the association of this polymorphism with breast cancer risk. A computerized literature search was systematically carried out in PubMed, EMBASE, ScienceDirect, China National Knowledge Infrastructure and Wanfang Databases, to identify the published case-control studies about the relationship between ABCB1 G2677T/A polymorphism and breast cancer risk. The strength of association was assessed by odds ratios (ORs) with 95% confidence intervals (CIs). Totally, six studies including 4,791 cases and 7,042 controls were included in the present meta-analysis. The results of quantitative synthesis suggested that there was no significant association between ABCB1 G2677T/A polymorphism and breast cancer risk in overall comparisons under four genetic models (heterozygote: OR= 1.01, 95%CI= 0.92-1.09, P= 0.90; homozygote: OR= 1.01, 95%CI= 0.65-1.55, P= 0.97; recessive model: OR= 1.06, 95%CI= 0.75-1.50, P= 0.76; dominant model: OR= 0.98, 95%CI= 0.77-1.24, P= 0.85). Similarly, no significant association was observed in the stratification analyses by ethnicity and control source. In conclusion, this meta-analysis suggested that ABCB1 G2677T/A polymorphism was not associated with genetic susceptibility to breast cancer.

1 January 2015 in Biomedical Journal
Verified
Journal Article
Closed access
HLHongchao Liu
Hongchao Liu
YFYan-Ming Feng
Yan-Ming Feng
LMLi-Min Ma
Li-Min Ma
LRLin-Hai Ruan
Lin-Hai Ruan

29 June 2023 in Frontiers in Neurology
Verified
Journal Article
Open access
HLHongchao Liu
Hongchao Liu
ZWZhihao Wei
Zhihao Wei
YZYu Zhang
Yu Zhang
KSKangke Shi
Kangke Shi
JLJiaqiong Li
Jiaqiong Li
Background: Transforming growth factor-β (TGF-β) is a multifunctional cytokine with an important role in tissue development and tumorigenesis. TGF-β can inhibit the function of many immune cells, prevent T cells from penetrating into the tumor center, so that the tumor cells escape from immune surveillance and lead to low sensitivity to immunotherapy. However, its potential roles in predicting clinical prognosis and tumor microenvironment (TME) immune features need to be deeply investigated in glioblastoma (GBM).Methods: The TCGA-GBM dataset was obtained from the Cancer Genome Atlas, and the validation dataset was downloaded from Gene Expression Omnibus. Firstly, differentially expressed TGF-β genes (DEGs) were screened between GBM and normal samples. Then, univariate and multivariate Cox analyses were used to identify prognostic genes and develop the TGF-β risk model. Subsequently, the roles of TGF-β risk score in predicting clinical prognosis and immune characteristics were investigated.Results: The TGF-β risk score signature with an independent prognostic value was successfully developed. The TGF-β risk score was positively correlated with the infiltration levels of tumor-infiltrating immune cells, and the activities of anticancer immunity steps. In addition, the TGF-β risk score was positively related to the expression of immune checkpoints. Besides, the high score indicated higher sensitivity to immune checkpoint inhibitors.Conclusions: We first developed and validated a TGF-β risk signature that could predict the clinical prognosis and TME immune features for GBM. In addition, the TGF-β signature could guide a more personalized therapeutic approach for GBM.

1 January 2023 in Technology in Cancer Research & Treatment
Verified
Journal Article
Open access
HLHongchao Liu
Hongchao Liu
ZWZhihao Wei
Zhihao Wei
KSKangke Shi
Kangke Shi
YZYu Zhang
Yu Zhang
JLJiaqiong Li
Jiaqiong Li
Glioblastoma is the most frequent form of malignant brain tumor. Cytoplasmic polyadenylation element binding protein 4 (CPEB4) is overexpressed and involved in the tumorigenesis and metastasis of glioblastoma. miR-130a-3p has been revealed to be aberrantly expressed in tumors and has aroused wide attention. In present study, we would like to investigate the effect and potential mechanism of miR-130a-3p on the proliferation and migration in glioblastoma. The relative expression levels of miR-130a-3p and CPEB4 in glioblastoma cell lines were detected by real-time quantitative polymerase chain reaction. Cell viability and migration were detected by methylthiazolyl tetrazolium assay and transwell assay, and cell cycle analysis was detected by flow cytometry. The expression of CPEB4 protein and epithelial-mesenchymal transition associated markers were detected by western blot. Bioinformatics and luciferase activity analysis were used to verify the targeting relationship between miR-130a-3p and CPEB4. We observed that the expression of CPEB4 was upregulated while that of miR-130a-3p was downregulated in glioblastoma cell lines. CPEB4 was validated as a target of miR-130a-3p by luciferase activity assay. Increased levels of miR-130a-3p inhibited the proliferation and migration of the glioblastoma cells and the overexpression of miR-130a-3p inhibited epithelial-mesenchymal transition. However, CPEB4 overexpression resisted the inhibitory effects of miR-130a-3p. Our study elucidates CPEB4 is upregulated because of the downregulated miR-130a-3p in glioblastoma, which enhances the glioblastoma growth and migration, suggesting a potential therapeutic target for the disease.